Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

Novo Nordisk just did Eli Lilly stock a huge favor.

Eli Lilly (LLY) stock announced seventh Innovent partnership with $350M upfront and $8.5B milestone potential for joint ...

Could these two companies be biotech giants in the making?

The share price of Eli Lilly (NYSE: LLY) jumped last week after the drugmaker reported strong sales of its GLP-1 weight-loss ...

Eli Lilly ( LLY 1.41%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

The rally in Lilly also pressured shares of its main weight-loss rival, Danish drugmaker Novo Nordisk ( NVO ), for a second ...

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion ...